Tonix Pharmaceuticals Holding Corp. 8K

Tonix Pharmaceuticals secured a second major commercial payer (GPO) agreement for TONMYA, expanding its U.S. commercial insurance coverage to roughly 52 million lives.

Tonix Pharmaceuticals Holding Corp. announced that, effective June 1, 2026, it entered into a second commercial payer agreement through a leading group purchasing organization to provide coverage for TONMYA, its newly FDA‑approved fibromyalgia treatment, adding access for approximately 17 million additional U.S. commercially insured lives and bringing total commercial coverage via two GPOs to about 52 million lives, or 29% of the U.S. commercial market, alongside expanding Medicaid availability and ongoing Medicare discussions.

Filing Facts

CIK

1430306

Ticker

-

Form

8K

Source Type

sec

Accession

0001493152-26-027621

Alert Tier

6